17 / 38
EVEROLIMUS
TARGETED AGENTS
Patients with advanced, progressive, nonfunctional NET of lung or GI
origin (N=302)
- Well differentiated (G1/G2)
- Absence of active symptoms or any history of carcinoid syndrome
- Pathologically confirmed advanced disease
- rDP≤ 6 months
Primary endpoint: central PFS
Everolimus 10 mg/day
(N=205)
Placebo
(N=97)
Stratified by
:
- Prior SSA treatment (yes
vs no)
- Tumor origin (A vs B)*
- WHO PS (0 vs 1)
RANDOMISE
2:1
Yao JC, et al. Lancet 2016; 387: 968–77
RADIANT-4
*Stratum A: Appendix, Cecum, Jejunum, Ileum, Duodenum or UK
*Stratum B: Lung, Stomach, Rectum, Colon except cecum